HAON Life Sciences
Dublin
About HAON Life Sciences
It specializes in developing innovative cell therapies, with a primary focus on addressing neonatal brain injuries caused by hypoxic-ischemic encephalopathy (HIE). This condition, resulting from oxygen deprivation during or shortly after birth, is a leading cause of neonatal deaths and long-term neurological impairments, such as cerebral palsy and epilepsy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $11.7M
- Last round: Grant (Apr 2025)
- Website: haonco.com
Social Profiles
Canonical: https://fsome.com/organization/haon-life-sciences-28107 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.